Form 8-K - Current report:
SEC Accession No. 0001746473-24-000169
Filing Date
2024-11-07
Accepted
2024-11-07 16:14:36
Documents
15
Period of Report
2024-11-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K plrx-20241107.htm   iXBRL 8-K 30817
2 EX-99.1 EARNINGS RELEASE a3q2024exhibit991.htm EX-99.1 65319
6 image_0.jpg GRAPHIC 13148
  Complete submission text file 0001746473-24-000169.txt   245658

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT plrx-20241107.xsd EX-101.SCH 1785
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT plrx-20241107_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT plrx-20241107_pre.xml EX-101.PRE 12510
17 EXTRACTED XBRL INSTANCE DOCUMENT plrx-20241107_htm.xml XML 2735
Mailing Address 331 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 331 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 650-481-6770
PLIANT THERAPEUTICS, INC. (Filer) CIK: 0001746473 (see all company filings)

EIN.: 474272481 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39303 | Film No.: 241435909
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)